http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 16:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Jun+17/26660390.html si-local-file:///var/storage/secattach/20260617/26660390.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Jun+17/26660390.html Wed, 17 Jun 2026 16:30:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Jun+17/26660390.html si-local-file:///var/storage/secattach/20260617/26660390.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+Jun+17/26660390.html Wed, 17 Jun 2026 16:30:00 -0400 HURA O.10076388 http://www.streetinsider.com/Analyst+Comments/TuHURA+Biosciences+%28HURA%29+Reiterated+at+Market+Outperform+by+Citizens+/26649597.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $9.00 price target on TuHURA Biosciences (NASDAQ: HURA).</p><p>The analyst commented, "We are encouraged to see TuHURA Biosciences kick off clinical development in the acute myeloid leukemia (AML) space, where menin inhibitors have demonstrated that significant value can be created. HURA announced the IND filing for anti-VISTA mAb, TBS-2025, after the FDA aligned with prior guidance on the development pathway for monotherapy and combination with menin inhibitors for AML. Following written responses related to the company's proposed Phase 1b/2 development plan, HURA is targeting study initiation in 2H26. We maintain our http://www.streetinsider.com/Analyst+Comments/TuHURA+Biosciences+%28HURA%29+Reiterated+at+Market+Outperform+by+Citizens+/26649597.html Tue, 16 Jun 2026 05:17:41 -0400 HURA http://www.streetinsider.com/FDA/TuHURA+Biosciences+files+IND+for+TBS-2025+antibody+in+blood+cancers/26644300.html <p>TuHURA Biosciences Inc. (NASDAQ: HURA) filed an Investigational New Drug application with the U.S. Food and Drug Administration for its TBS-2025 VISTA inhibiting antibody to treat molecularly defined subsets of acute myeloid leukemia and other blood-related cancers.</p> <p>The IND filing follows guidance from the FDA on the development pathway for both monotherapy and combination treatments with menin inhibitors for AML. The FDA indicated that a requested meeting would not be necessary and will provide written responses to questions about the company's proposed Phase 1b/2 development plan for TBS-2025 in AML.</p> <p>TuHURA targets initiation of the Phase 1b/2 study in the second half http://www.streetinsider.com/FDA/TuHURA+Biosciences+files+IND+for+TBS-2025+antibody+in+blood+cancers/26644300.html Mon, 15 Jun 2026 07:49:38 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/FDA/TuHURA+Biosciences+files+IND+for+TBS-2025+antibody+in+blood+cancers/26644300.html <p>TuHURA Biosciences Inc. (NASDAQ: HURA) filed an Investigational New Drug application with the U.S. Food and Drug Administration for its TBS-2025 VISTA inhibiting antibody to treat molecularly defined subsets of acute myeloid leukemia and other blood-related cancers.</p> <p>The IND filing follows guidance from the FDA on the development pathway for both monotherapy and combination treatments with menin inhibitors for AML. The FDA indicated that a requested meeting would not be necessary and will provide written responses to questions about the company's proposed Phase 1b/2 development plan for TBS-2025 in AML.</p> <p>TuHURA targets initiation of the Phase 1b/2 study in the second half http://www.streetinsider.com/FDA/TuHURA+Biosciences+files+IND+for+TBS-2025+antibody+in+blood+cancers/26644300.html Mon, 15 Jun 2026 07:49:38 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/FDA/TuHURA+Biosciences+files+IND+for+TBS-2025+antibody+in+blood+cancers/26644300.html <p>TuHURA Biosciences Inc. (NASDAQ: HURA) filed an Investigational New Drug application with the U.S. Food and Drug Administration for its TBS-2025 VISTA inhibiting antibody to treat molecularly defined subsets of acute myeloid leukemia and other blood-related cancers.</p> <p>The IND filing follows guidance from the FDA on the development pathway for both monotherapy and combination treatments with menin inhibitors for AML. The FDA indicated that a requested meeting would not be necessary and will provide written responses to questions about the company's proposed Phase 1b/2 development plan for TBS-2025 in AML.</p> <p>TuHURA targets initiation of the Phase 1b/2 study in the second half http://www.streetinsider.com/FDA/TuHURA+Biosciences+files+IND+for+TBS-2025+antibody+in+blood+cancers/26644300.html Mon, 15 Jun 2026 07:49:38 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/FDA/TuHURA+Biosciences+files+IND+for+TBS-2025+antibody+in+blood+cancers/26644300.html <p>TuHURA Biosciences Inc. (NASDAQ: HURA) filed an Investigational New Drug application with the U.S. Food and Drug Administration for its TBS-2025 VISTA inhibiting antibody to treat molecularly defined subsets of acute myeloid leukemia and other blood-related cancers.</p> <p>The IND filing follows guidance from the FDA on the development pathway for both monotherapy and combination treatments with menin inhibitors for AML. The FDA indicated that a requested meeting would not be necessary and will provide written responses to questions about the company's proposed Phase 1b/2 development plan for TBS-2025 in AML.</p> <p>TuHURA targets initiation of the Phase 1b/2 study in the second half http://www.streetinsider.com/FDA/TuHURA+Biosciences+files+IND+for+TBS-2025+antibody+in+blood+cancers/26644300.html Mon, 15 Jun 2026 07:49:38 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html <div class="xn-content"> <p class="prntac"><i>The IND is aligned with guidance previously provided by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for </i>Acute Myeloid Leukemia (AML)</p><p class="prntac"><i>The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML </i></p><p class="prntac"><i>The Company is targeting initiation of the Phase 1b/2 study in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html Mon, 15 Jun 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html <div class="xn-content"> <p class="prntac"><i>The IND is aligned with guidance previously provided by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for </i>Acute Myeloid Leukemia (AML)</p><p class="prntac"><i>The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML </i></p><p class="prntac"><i>The Company is targeting initiation of the Phase 1b/2 study in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html Mon, 15 Jun 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html <div class="xn-content"> <p class="prntac"><i>The IND is aligned with guidance previously provided by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for </i>Acute Myeloid Leukemia (AML)</p><p class="prntac"><i>The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML </i></p><p class="prntac"><i>The Company is targeting initiation of the Phase 1b/2 study in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html Mon, 15 Jun 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html <div class="xn-content"> <p class="prntac"><i>The IND is aligned with guidance previously provided by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for </i>Acute Myeloid Leukemia (AML)</p><p class="prntac"><i>The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML </i></p><p class="prntac"><i>The Company is targeting initiation of the Phase 1b/2 study in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html Mon, 15 Jun 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html <div class="xn-content"> <p class="prntac"><i>The IND is aligned with guidance previously provided by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for </i>Acute Myeloid Leukemia (AML)</p><p class="prntac"><i>The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML </i></p><p class="prntac"><i>The Company is targeting initiation of the Phase 1b/2 study in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html Mon, 15 Jun 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html <div class="xn-content"> <p class="prntac"><i>The IND is aligned with guidance previously provided by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for </i>Acute Myeloid Leukemia (AML)</p><p class="prntac"><i>The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML </i></p><p class="prntac"><i>The Company is targeting initiation of the Phase 1b/2 study in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html Mon, 15 Jun 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html <div class="xn-content"> <p class="prntac"><i>The IND is aligned with guidance previously provided by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for </i>Acute Myeloid Leukemia (AML)</p><p class="prntac"><i>The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML </i></p><p class="prntac"><i>The Company is targeting initiation of the Phase 1b/2 study in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html Mon, 15 Jun 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html <div class="xn-content"> <p class="prntac"><i>The IND is aligned with guidance previously provided by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for </i>Acute Myeloid Leukemia (AML)</p><p class="prntac"><i>The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML </i></p><p class="prntac"><i>The Company is targeting initiation of the Phase 1b/2 study in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> http://www.streetinsider.com/PRNewswire/TuHURA+Biosciences+Files+Investigational+New+Drug+Application+for+Evaluation+of+the+TBS-2025+VISTA+Inhibiting+Antibody+in+Molecularly+Defined+Subsets+of+AML+and+Other+Blood+Related+Cancers/26644298.html Mon, 15 Jun 2026 07:45:00 -0400 A.06822034 HURA O.10076388 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+May+26/26576275.html si-local-file:///var/storage/secattach/20260529/26576275.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+May+26/26576275.html Fri, 29 May 2026 17:00:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+May+26/26576275.html si-local-file:///var/storage/secattach/20260529/26576275.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+May+26/26576275.html Fri, 29 May 2026 17:00:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TuHURA+Biosciences%2C+Inc.++For%3A+May+28++Filed+by%3A+Bianco+James+A./26575902.html si-local-file:///var/storage/secattach/20260529/26575902.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TuHURA+Biosciences%2C+Inc.++For%3A+May+28++Filed+by%3A+Bianco+James+A./26575902.html Fri, 29 May 2026 16:37:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TuHURA+Biosciences%2C+Inc.++For%3A+May+28++Filed+by%3A+Bianco+James+A./26575902.html si-local-file:///var/storage/secattach/20260529/26575902.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TuHURA+Biosciences%2C+Inc.++For%3A+May+28++Filed+by%3A+Bianco+James+A./26575902.html Fri, 29 May 2026 16:37:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TuHURA+Biosciences%2C+Inc.++For%3A+Mar+31/26507899.html si-local-file:///var/storage/secattach/20260515/26507899.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TuHURA+Biosciences%2C+Inc.++For%3A+Mar+31/26507899.html Fri, 15 May 2026 17:21:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TuHURA+Biosciences%2C+Inc.++For%3A+Mar+31/26507899.html si-local-file:///var/storage/secattach/20260515/26507899.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TuHURA+Biosciences%2C+Inc.++For%3A+Mar+31/26507899.html Fri, 15 May 2026 17:21:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+May+15/26507757.html si-local-file:///var/storage/secattach/20260515/26507757.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+May+15/26507757.html Fri, 15 May 2026 17:11:00 -0400 HURA O.10076388 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+May+15/26507757.html si-local-file:///var/storage/secattach/20260515/26507757.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TuHURA+Biosciences%2C+Inc.++For%3A+May+15/26507757.html Fri, 15 May 2026 17:11:00 -0400 HURA O.10076388 http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26507483.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p><p>"I am very pleased with the progress we have made this past quarter as we continue to execute upon our corporate and development strategy. Importantly, we recently established a <money>$50 million</money> non-equity-based source of operating capital in the form of credit facility with our http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26507483.html Fri, 15 May 2026 17:00:00 -0400 HURA O.10076388 http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26507483.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p><p>"I am very pleased with the progress we have made this past quarter as we continue to execute upon our corporate and development strategy. Importantly, we recently established a <money>$50 million</money> non-equity-based source of operating capital in the form of credit facility with our http://www.streetinsider.com/Press+Releases/TuHURA+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26507483.html Fri, 15 May 2026 17:00:00 -0400 HURA O.10076388